-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirmitegravir in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pirmitegravir in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pirmitegravir in Human Immunodeficiency Virus (HIV) Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Urethral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Urethral Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Urethral Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afamitresgene Autoleucel in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Afamitresgene Autoleucel in Gastric Cancer Drug Details: ADPA-2M4 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lixadesiran + Pixofisiran in Abdominal Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lixadesiran + Pixofisiran in Abdominal Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lixadesiran + Pixofisiran in Abdominal Obesity Drug Details: STP705...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lixadesiran + Pixofisiran in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lixadesiran + Pixofisiran in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lixadesiran + Pixofisiran in Solid Tumor Drug Details: STP705...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lixadesiran + Pixofisiran in Nonmelanomatous Skin Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lixadesiran + Pixofisiran in Nonmelanomatous Skin Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lixadesiran + Pixofisiran in Nonmelanomatous Skin Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lixadesiran + Pixofisiran in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lixadesiran + Pixofisiran in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lixadesiran + Pixofisiran in Basal...
-
Thematic Analysis
Low Cost Evolution Travel and Tourism – Thematic Intelligence
Low-Cost Evolution Travel and Tourism Thematic Report Overview Travel companies are targeting a wider range of customers as airfares and hotel tariffs have become affordable in recent years. The travel industry now encompasses every type of traveler, and this has resulted in the rising popularity of low-cost travel and tourism operators. Travel apps such as Airbnb and Uber have been at the forefront of the low-cost evolution. These apps shape travelers’ spending habits by sending push notifications regarding last-minute deals...
-
Analyst Opinions
Budget Hotels Market Trends and Analysis by Region, Deals and Competitive Landscape
Budget Hotels Market Report Overview The budget hotels market was valued at $95.92 billion in 2022. The decrease in COVID travel restrictions has led to a growing number of budget-conscious travelers, the rise of online booking platforms, and increasing travel and tourism, which became the major contributors to the growth of budget hotel revenue during 2022. Buy the Full Report for Additional Insights on the Budget Hotels Market Download a Free Report Sample The budget hotels market research report provides...